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Purpose: Half of all patients with non-small cell lung cancer
(NSCLC) are 70 years or older at the time of diagnosis. Surgery is
an option for fit elderly patients with early stage disease, but rates of
disease recurrence after surgical resection are not well described.
We report the outcomes in elderly patients (70 years or older) with
stage I NSCLC after surgical resection.
Patients and Methods: We conducted a retrospective study of
patients diagnosed with stage I NSCLC after surgical resection at
Washington University School of Medicine-Alvin J. Siteman Cancer
Center from 1990 to 2000. Demographic, pathologic, treatment, and
follow-up data were collected. Recurrence rates and overall survival
were calculated by the Kaplan-Meier method. Multivariate Cox
proportional hazards models were used to detect associations be-
tween potential prognostic factors and survival and recurrence.
Results: Of the 715 patients with stage I NSCLC, 286 were 70 years
or older at diagnosis. In this elderly cohort, the median age was 74
years (range, 70–89 years) and 140 of them were women (49%).
Lobectomy was performed in 237 patients (83%) whereas 43 pa-
tients (15%) had a wedge or segmental resection, and six patients
(2%) underwent pneumonectomy. Clinical and pathologic charac-
teristics were not statistically different between the elderly and
younger cohorts, with the exception that older patients were more
likely to be white (90% versus 80%, p  0.0003) and less likely to
be smokers (88% versus 95%, p  0.019) compared with the
younger cohort. With a median follow-up of 4.6 years, the overall
5-year survival rate was 52% with a 5-year recurrence rate of 24%.
In comparison, the patients younger than 70 years had a 5-year
survival rate of 67% (p  0.001) and a 5-year recurrence rate of 24%.
Conclusions: Although overall survival was worse in elderly
patients, estimated disease recurrence rates after resection were
identical.
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Lung cancer is the most common cause of cancer-relateddeath in the United States, with non-small cell lung cancer
(NSCLC) accounting for 87% of all cases.1 A better under-
standing of NSCLC in elderly patients is important for
several reasons. Lung cancer is a disease of the elderly, with
the median age at diagnosis around 70 years in the United
States.2 With continued increase in life expectancy, it is
widely expected that the proportion of elderly patients with
lung cancer will continue to increase in the coming years.
Although there is consensus that surgery is not appropriate
therapy for patients (regardless of age) with poor perfor-
mance status or extensive comorbid conditions, elderly pa-
tients may not be offered appropriate surgical options, even in
the absence of comorbidities.3 It has also been suggested that
NSCLC in the elderly has a more indolent course.4
An improved understanding of the outcomes in resected
NSCLC in the elderly would help guide adjuvant chemother-
apy decisions, particularly because the potential benefits of
adjuvant chemotherapy would be diminished by competing
causes of mortality. We have demonstrated previously that
individual patient comorbidity reduces overall survival in
patients with resected stage I NSCLC, and comorbidities
clearly increase with increasing age.5,6 In making adjuvant
treatment decisions, risks of death from therapy-related tox-
icities and comorbidities must be weighed against risk of
death from recurrent cancer.
We conducted a single-institution retrospective study to
characterize the outcomes of elderly patients with early-stage
NSCLC and compared the outcomes between the elderly and
younger cohorts. We restricted to study the resected stage I
NSCLC to avoid the confounding effects of adjuvant therapy
in resected stage II and III NSCLC.
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PATIENTS AND METHODS
We identified all patients who underwent surgical re-
section for stage I NSCLC at Washington University School
of Medicine-Alvin J. Siteman Cancer Center from 1990 to
2000 through the Barnes-Jewish Hospital tumor registry.
Patients included in this study had pathologically documented
stage IA or IB disease, negative surgical margins, and no
history of lung cancer. Outcomes and risk factors in this
patient dataset have been published previously.7 Clinical and
pathologic information was obtained from individual patient
charts. Data were collected regarding patient demographics
(age, date of birth, race), pathologic factors (tumor stage,
size, histologic subtype, grade of differentiation), treatment
(extent of surgery, and use of adjuvant chemotherapy and
radiation therapy), and outcomes (survival time, recurrence,
and second primary lung cancers). Tobacco use was docu-
mented in the tumor registry for most patients seen after
1996. Grade of differentiation was assigned based on stan-
dard American Joint Committee on Cancer criteria. For those
tumors that displayed a range of cellular differentiation, the
least differentiated portion of the tumor was recorded. For
example, tumors that were described in the original pathology
report as “moderately to poorly differentiated” or “moderate
to high grade” were assigned a grade of “poor.” Visceral
pleural involvement was documented as follows: p0  tumor
extends into elastic layer but not beyond, p1  tumor extends
beyond elastic layer but not to the pleural surface, and p2 
tumor is exposed on the visceral surface but does not involve
parietal pleura.8 In all cases where the original pathology
report raised the possibility of pleural involvement (101
patients), original pathology slides were re-reviewed by one
of us (C.R.M.) who was blinded to the outcome, to ensure
appropriate tumor classification. Four cases with the involve-
ment of parietal pleura (T3 disease) were identified and these
were excluded from further analysis. Final pathologic tumor
classification was assigned for the remaining 715 patients
according to 2002 American Joint Committee on Cancer
criteria.9
For the purposes of comparison, patients were divided
into two cohorts based on age at diagnosis: 70 or 70
years. Estimated overall survival rates and recurrence rates
were calculated using the Kaplan-Meier method. Overall
survival was defined as the time from the surgery to the date
of last follow-up or death. Patients who were not known to be
dead were censored at the date of last clinical contact. For
the recurrence analysis, time to recurrence was defined as the
time from the date of surgery to the date of recurrence.
Patients who died without recurrence were censored at the
date of death, whereas those who were alive without recur-
rence were censored at the date of last contact. Log-rank tests
were conducted to identify significant factors related to over-
all survival or recurrence. Multivariate Cox models were
fitted to identify independent risk factors. In the analysis of
recurrence, competing risk methods of Fine and Gray10 were
also used as a sensitivity analysis to account for the potential
competing effect of death. Only these factors with p  0.2 in
the univariate analysis were considered for constructing the
corresponding multivariate models. The statistical analysis was
performed with the statistical packages SAS (SAS Institutes,
Cary, NC) and cmprsk R (http://biowww.dfci.harvard.edu/gray).
A p value 0.05 was considered to indicate statistical signifi-
cance and all tests were two sided.
RESULTS
Of the 715 patients who underwent surgery during the
study period, 286 patients were 70 years old at the time of
diagnosis (see Table 1). The median age of the elderly cohort
was 74 years (range, 70–89 years). The gender distribution
was roughly equal with 140 women (49%). Lobectomy was
performed in 237 patients (83%), wedge or segmental resec-
tion in 43 (15%), and pneumonectomy in six (2%). Tumor (T)
status was distributed evenly: 142 patients (50%) had T1
tumors (see Table 2). The median tumor size was 2.5 cm,
with 103 patients (36%) having a tumor size of 3 cm. The
most common histology was adenocarcinoma (43%), fol-
lowed by squamous cell carcinoma (37%), and bronchioal-
veolar carcinoma (8%).
Clinical and pathologic characteristics were not statis-
tically different between the elderly and younger cohorts,
with the exception that older patients were more likely to be
white (90% versus 80%, p  0.0003) and less likely to be
smokers (88% versus 95%, p  0.019). The 30-day mortality
was increased in the elderly cohort, 5.6% as compared with
1% in the younger group (p  0.01) (see Fig. 1). The
duration of follow-up for the elderly cohort was less than that
for the younger cohort, 4.6 versus 5.4 years, respectively (p 
0.001), most likely corresponding to the shorter median
survival time in the elderly cohort (5.5 versus 8.3 years, p 
0.001) (see Table 3). Five-year survival rates were 52 and
67%, respectively (see Fig. 2). A total of 56 elderly patients
(19%) developed recurrent disease, with a median of 1.9
TABLE 1. Clinical Characteristics of Resected Stage I
NSCLC Subjects by Age at Diagnosis
Variables
Age >70 yr Age <70 yr
pN % N %
Total subjects 286 40 429 60




Male 146 51 237 55 0.2704
Female 140 49 192 45
Ethnicity
White 258 90 344 80 0.0001
Black 19 7 72 17
Other/unknown 2 1 2 0
Type of surgical resection
Wedge or segmental 43 15 46 11 0.1098
Lobectomy 237 83 361 84
Pneumonectomy 6 2 17 4
Adjuvant treatment
Adjuvant radiotherapy 2 1 5 1 0.5351
Adjuvant chemotherapy 0 0 6 1 0.0446
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years to diagnosis, whereas 106 younger patients (25%)
developed recurrent disease at a median of 1.4 years. How-
ever, Kaplan-Meier estimates of freedom from recurrence
were nearly identical, with estimated 3- and 5-year recurrence
rates in the elderly patients of 19 and 24%, respectively, and
rates of 20 and 24%, respectively, in the younger patients (see
Fig. 2). Elderly and younger patients had similar rates of local
recurrence (14 and 17%, respectively, p  0.26). Younger
patients experienced distant relapse as the initial site of recur-
rence more frequently than older patients (15% versus 10%),
although this did not reach statistical significance (p  0.075).
Risk factors for recurrence were evaluated in the el-
derly cohort. Risk was higher with pneumonectomy (two of
six, 33%) or sublobar resection (13 of 43, 30%) as compared
with lobectomy (17%, p  0.006) and therefore resections
other than lobectomy were grouped. Local recurrence ac-
counted for the majority of relapse in sublobar resections
(nine of 13), whereas there were no local relapses in the six
TABLE 2. Pathologic Characteristics of Resected Stage I
NSCLC Subjects by Age at Diagnosis
Variables
Age >70 yr Age <70 yr
pN % N %
T classification
1 142 50 233 50 0.2985
2 144 50 196 50
Tumor size (cm)
Median 2.5 2.5 0.1829
0–3 cm 183 64 289 68
3.1–5 cm 68 24 89 21
5 cm 35 12 45 11
Histologic subtype
Adenocarcinoma 124 43 195 45 0.9029
Squamous cell 107 37 148 34
Bronchioalveolar 22 8 33 8
Neuroendocrine 9 3 14 3
Other 24 8 39 8
Cellular grade
Well differentiated 51 18 68 16 0.2940
Moderately
differentiated
144 50 196 46
Poorly differentiated 90 31 157 37
Pleural invasion
Present 70 24 79 18 0.0525
FIGURE 1. Kaplan-Meier curves for overall survival and
freedom from recurrence in the elderly cohort.
TABLE 3. Outcomes by Age at Diagnosis
Age >70 yr Age <70 yr p
Follow-up (yrs)
Median 4.6 5.4 0.0001
Overall survival
Median 5.5 yr 8.3 yr 0.0001
5 yr 52% 67%
Actual number of recurrences
Number (%) 56 (20) 106 (25)
Median time to recurrence (yrs) 1.9 1.4 0.7267
Kaplan-Meier estimates of
recurrence rates
3 yr 19% 20% 0.4248
5 yr 24% 24%
FIGURE 2. (A) Overall survival and (B) freedom from recur-
rence in younger versus elderly patients.
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elderly patients who underwent pneumonectomy. Univariate
analysis showed that three other factors were significantly
associated with increased recurrence rates: T2 lesions, larger
tumor size (3 cm), and pleural invasion (see Table 4). In the
multivariate analysis, independent predictors of recurrence
were tumor size 3 cm (p  0.002) and surgery other than
lobectomy (p  0.0003).
Similar analyses were performed to identify predictors
of overall survival in the elderly patients. In the univariate
analysis, T2 lesions, nonlobectomy, increased tumor size, and
squamous cell carcinoma were associated with decreased
survival. Perioperative (30-day) mortality was highest with
pneumonectomy (one of six patients, 17%) and were similar
between sublobar resection and lobectomy, 7 and 5%, respec-
tively (p  0.63). In the multivariate analysis, tumor size,
squamous cell carcinoma, and surgery other than lobectomy
persisted as independent risk factors for mortality (p  0.031,
0.050, and 0.043, respectively).
DISCUSSION
In this study, we showed that elderly patients who do
not die of other causes are equally as likely to develop
recurrent NSCLC as younger patients.
Several studies reported overall survival in elderly
patients with resected NSCLC, not necessarily restricted to
stage I disease. For example, a retrospective study from the
University of Turin, Italy, reported a 5-year survival rate of
40.1% in 258 elderly patients (age 70 years) in stages I to
IIIB.11 A study from Quebec, Canada, reported that the 5-year
survival of 500 patients 70 years old in stages I to IIIB was
34%.12 Investigators from the Mayo Clinic reported a 5-year
survival rate of 44% in 196 octagenarians with resected stage
I NSCLC.13 These results can be compared with the 55 to
72% 5-year survival rates reported in various other studies
involving patients of all age groups with resected stage I
NSCLC.14
In one of the largest studies, which compared outcomes
between younger and older patients, Cerfolio and Bryant4
matched patients older than 70 years with those younger than
70 years based on stage, pulmonary function, performance
status, histology, and type of pulmonary resection. This
included 241 patients with stage I disease. Older and younger
patients had similar 5-year survival rates of 51 and 58%,
respectively. However, when stage I patients were grouped
separately, the 5-year survival was 78% in the older patients
and 69% in the younger patients (p  0.02). Cancer recur-
rences and causes of death were not documented in this study,
but the authors suggest that elderly patients may have “less
virulent tumors.” Other smaller studies comparing survival
rates between elderly patients and younger counterparts have
shown similar or slightly inferior survival in elderly patients
as compared with younger patients.15–20
Based on these series and other data, it is not clear
whether the underlying tumor biology is less aggressive in
elderly patients, leading to a lower likelihood of cancer
recurrence after resection. This question cannot be addressed
by merely examining overall survival, because of the multiple
confounders. We chose to study patients with resected stage
I NSCLC to have as homogenous a population as clinically
possible and focused on recurrence rate as the primary end-
point. In addition, 1% of patients in our study received
adjuvant (or neoadjuvant) chemotherapy or radiation limiting
the confounding effects of adjuvant therapy.
As in most other studies, our elderly cohort did have a
lower 5-year survival rate than the younger cohort (52%
versus 67%, p  0.001) (Fig. 2). A portion of this difference
can be ascribed to the increased 30-day, perioperative mor-
tality of 5.6% in the elderly cohort. In the Kaplan-Meier
analysis for recurrence, such patients were censored who died
without evidence of recurrent cancer. With this methodology,
we found that the two cohorts had almost identical estimated
recurrence rates. Furthermore, the median time to recurrence






HR (95% CI) p Univariate p
Multivariate
HR (95% CI) p
Age (per yr) 0.57 — — 0.058 1.03 (0.99–1.06) 0.16
Male vs. female 0.13 1.60 (0.93–2.74) 0.09 0.055 1.31 (0.97–1.77) 0.08
White vs. others 0.49 — — 0.19 1.42 (0.75–2.70) 0.28
Grade 0.64 — — 0.28 — —
Comorbiditya 0.12 — — 0.38 — —
Smokinga 0.36 — — 0.32 — —
T2 vs. T1 tumorb 0.006 — — 0.006 — —
Tumor size 3 cm 0.008 2.37 (1.36–4.10) 0.002 0.009 1.43 (1.03–1.97) 0.03
Squamous cell 0.31 — — 0.005 1.38 (1.00–1.89) 0.05
Pleural invasion 0.048 1.64 (0.94–2.86) 0.08 0.18 1.33 (0.95–1.87) 0.10
Nonlobectomy 0.006 3.14 (1.69–5.85) 0.001 0.003 1.50 (1.01–2.21) 0.04
a Not considered in multivariate models because of too many missing values.
b Not included in the multivariate models because of correlation with tumor size.
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in the elderly group (1.9 years) was not significantly different
than that in the younger group (1.4 years, p  NS). These
findings suggest that the elderly patients with lung cancer do not
necessarily have a “benign” course and that the survival differ-
ences are caused by noncancer, age-related comorbidities.
Our study has the usual limitations associated with all
retrospective studies. Despite our extensive chart review and
lengthy follow-up, some recurrences may not have been
identified. Patients may have died without a complete eval-
uation and had an unrecognized cancer recurrence. Such
patients would have been censored from our recurrence
analysis at the time of death. If at all, this could have only led
to underestimatation of the recurrence rate. It is unlikely that
this potential methodologic bias affected our conclusions.
In summary, similar recurrence rates between elderly
and younger patients suggest that the underlying cancer
biology in these patients is not significantly different and
elderly patients do not have a more indolent disease when
compared with younger patients. Treatment decisions regard-
ing adjuvant chemotherapy in the elderly should be guided by
performance status and severity of comorbid conditions
rather than by chronological age alone.
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